Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2851 - 2875 of 3092 in total
Experimental
Experimental
Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was sold under the tradename...
Withdrawn
Experimental
Experimental
S-3APG (S-3-[3-amino-phthalimido]-glutarimide) is a derivative of thalidomide with dual activity against B-cell neoplasias.
Investigational
Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Investigational
Experimental
Hydroxytriptolide has been investigated for the treatment of Rheumatoid Arthritis.
Investigational
Investigational
Vet approved
Displaying drugs 2851 - 2875 of 3092 in total